Drug Treatment

Symphony suite of tests for Breast Cancer – pro

Symphony suite of tests includes Mammaprint, BluePrint and TargetPrint. According to the online article titled “Comparison of MammaPrint, BluePrint, and TargetPrint with Clinical Parameters in Patients with Breast Cancer: Findings from a Prospective United States Cohort”, it states that the multigene signature MammaPrint, as well as BluePrint and TargetPrint, provides additional information for treatment guidance. By combining MammaPrint with

Read more
TDM1- 2012 update -pro

Trastuzumab emtansine (INN), variously called L trastuzumab-DM1 or trastuzumab-MCC-DM1, or  T-DM1 is an antibody-drug conjugate consisting of the antibody trastuzumab (Herceptin) linked to a cytotoxic agent that is a derivative of maytansine (DM1). Is is promising drug and it is in several studies. EMILIA, a phase III trial of 991 people with HER2-positive unresectable locally advanced or metastatic breast cancer, comparing T-DM1 versus capecitabine

Read more
Tamoxifen for breast pain – pro

Tamoxifen can be used off-label to treat breast pain (mastalgia), because it reduces estrogen levels that cause breast swelling.In one study, tamoxifen relieved pain in more than two-thirds of women who had a history of severe breast pain. Experts disagree about the use of tamoxifen for breast pain, because it has important side effects and risks. One double blind randomized comparatiove study(RCT)  compared tamoxifen 20 mg daily versus placebo.

Read more
Tykerb with Herceptin – pro

Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2–overexpressing breast cancer in several phase II and III clinical trials. Tykerb is approved with capecitabine or Femara. Data from the first-ever randomized, multi-center, open label Phase III trial examining the combination of two targeted therapies, Tykerb™ (lapatinib ditosylate) tablets

Read more
Tarceva for breast cancer – pro

EGFR inhibition has been of great interest as a potential treatment for researchers working in breast cancer. Unfortunatley, gelfitinib and Iressa phase II studies in heavily pre-treated patients did not show much activity.   This observation also appears to extend to another EGFR TKI, namely erlotinib. A phase II trial of erlotinib (as monotherapy of 150 mg/day) in locally advanced or metastatic breast cancer (n = 69) was conducted with 2 arms,

Read more
Pertuzumab, Herceptin, docetaxel for later stage metastatic breast cancer – pro

On June 11, 2012, U.S. Food and Drug Administration (FDA) has approved PerjetaTM (pertuzumab). Perjeta is approved in combination with Herceptin® (trastuzumab) and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.  This approval is based on data from a Phase III study which showed that people with previously untreated

Read more
Herceptin and Arimidex for HER+, ER/PR+ Metastatic Breast Cancer – pro

Preclinical evidence suggests Herceptin can restore and amplify responsiveness to hormonal therapy. The combination of Tykerb and Femara is FDA approved and is thought to work through this mechanism. A randomized phase III TAnDEM studyinvestigated Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor in receptor 2-positive, hormone receptor-positive metastatic breast

Read more
Lapatinib (Tykerb) – pro

Lapatinib (Tykerb) is an oral drug that has been shown to have activity in HER+ breast cancer in several phase II and III clinical trials. Specifically, Lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate Lapatinib as adjuvant treatment in early-stage disease. Lapatinib is indicated

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39